Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock

CORAL GABLES, FL— Catalyst Pharmaceuticals , Inc. (NASDAQ:CPRX), a $2.66 billion market cap pharmaceutical company, recently disclosed that Jeffrey Del Carmen, the company’s Chief Commercial Officer, sold 30,423 shares of the company’s common stock. The transaction, which took place on March 3, 2025, was executed at a price of $22.89 per share, totaling $696,382. The stock currently trades at $21.89, with analysts setting price targets between $29 and $40.

The shares were sold for personal reasons, as noted in the filing, and not due to any disagreement with the company. Following this transaction, Del Carmen no longer holds any shares in Catalyst Pharmaceuticals. The company maintains excellent financial health according to InvestingPro analysis, with an impressive 85.64% gross profit margin and strong cash flow generation.

Catalyst Pharmaceuticals, headquartered in Coral Gables, Florida, specializes in the development and commercialization of pharmaceutical preparations. InvestingPro analysis indicates the company is currently undervalued, with 8 additional key insights available to subscribers through their comprehensive Pro Research Report.

In other recent news, Catalyst Pharmaceuticals reported impressive financial results for the fourth quarter of 2024, significantly exceeding both earnings and revenue forecasts. The company achieved an earnings per share (EPS) of $0.70, more than doubling the expected $0.32, while revenue climbed to $141.8 million, surpassing the forecasted $133.68 million. For the fiscal year 2024, Catalyst reported a total revenue of $491.7 million, exceeding the previously guided range of $475 million to $485 million. Looking ahead, the company has provided a revenue guidance for fiscal year 2025, projecting between $545 million and $565 million.

Stephens analyst Sudan Loganathan responded to these results by raising the price target for Catalyst Pharmaceuticals shares from $33.00 to $40.00 and maintaining an Overweight rating. This adjustment reflects confidence in the company’s growth trajectory, particularly due to strong sales of AGAMREE and the performance of FYCOMPA despite the loss of exclusivity. Catalyst Pharmaceuticals also provided an optimistic outlook for 2025, forecasting significant revenue contributions from its key products, including Firdapse and AGAMRI.

The company’s robust cash position at the end of 2024, with cash and cash equivalents totaling $517.6 million and no debt, enhances its capacity to invest in strategic growth opportunities. Catalyst’s CEO, Richard Daley, highlighted the company’s record revenue growth in 2024 and emphasized their strategic focus and market resilience. These recent developments underscore Catalyst Pharmaceuticals’ solid position in the market and its successful execution of growth strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.